Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Declines By 96.2%

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a significant drop in short interest in the month of April. As of April 30th, there was short interest totaling 269,068 shares, a drop of 96.2% from the April 15th total of 7,087,765 shares. Based on an average trading volume of 193,588 shares, the short-interest ratio is currently 1.4 days. Approximately 3.6% of the shares of the company are short sold.

Institutional Trading of VolitionRX

A number of hedge funds have recently made changes to their positions in VNRX. Armistice Capital LLC increased its stake in VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after acquiring an additional 887,351 shares during the last quarter. Geode Capital Management LLC increased its position in shares of VolitionRX by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 85,816 shares during the last quarter. Citadel Advisors LLC raised its holdings in shares of VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after buying an additional 135,775 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in shares of VolitionRX during the 2nd quarter valued at about $52,000. Finally, Squarepoint Ops LLC bought a new stake in VolitionRX in the 4th quarter worth approximately $34,000. 8.09% of the stock is owned by institutional investors.

VolitionRX Stock Up 1.7%

NYSEAMERICAN:VNRX traded up $0.04 during trading hours on Wednesday, hitting $2.36. 231,188 shares of the company’s stock traded hands, compared to its average volume of 450,694. The firm has a market cap of $19.09 million, a P/E ratio of -0.54 and a beta of 1.03. VolitionRX has a 52 week low of $2.01 and a 52 week high of $18.80. The business’s fifty day simple moving average is $3.42 and its two-hundred day simple moving average is $5.07.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on VNRX. D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Citigroup lowered VolitionRX to a “hold” rating in a report on Monday, April 20th. Finally, HC Wainwright lowered their price target on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.67.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.